Howard Hughes Medical Institute’s Jacobs Solutions J Stock Holding History

Howard Hughes Medical Institute’s Portfolio J Stock Details J Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-26	Closed	-$3.44K	–	269
2025 Q4	$3.44K	Hold	26	–	–	﹤0.01%	416
2025 Q3	$3.9K	Hold	26	–	–	﹤0.01%	384
2025 Q2	$3.42K	Buy	+26	New	+$3.21K	﹤0.01%	400

Other funds holding J

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Howard Hughes Medical Institute's J Position: Q1 2026 in Review

Howard Hughes Medical Institute sold out of Jacobs Solutions (J) in Q1 2026, closing a stake of 26 shares — an estimated $3.44K sold.

Howard Hughes Medical Institute first reported a position in J in Q2 2025 and held it in 3 quarters. The position peaked at $3.9K in Q3 2025. 913 funds tracked by Wall St. Rank hold J as of Q1 2026.

Howard Hughes Medical Institute reported no remaining Jacobs Solutions position as of Q1 2026 after selling out during the quarter.
Howard Hughes Medical Institute sold 26 Jacobs Solutions shares in Q1 2026, an estimated $3.44K.
Howard Hughes Medical Institute first reported a position in Jacobs Solutions in Q2 2025 and held it in 3 quarters.
Howard Hughes Medical Institute's Jacobs Solutions position peaked at $3.9K in Q3 2025.
913 funds tracked by Wall St. Rank held Jacobs Solutions as of Q1 2026.

Based on Howard Hughes Medical Institute's 13F filing for Q1 2026, filed 15 May 2026.